161 related articles for article (PubMed ID: 19955297)
1. Atazanavir-associated choledocholithiasis leading to acute hepatitis in an HIV-infected adult.
Jacques AC; Giguère P; Zhang G; Touchie C; la Porte CJ
Ann Pharmacother; 2010 Jan; 44(1):202-6. PubMed ID: 19955297
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
[TBL] [Abstract][Full Text] [Related]
3. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype.
Lankisch TO; Moebius U; Wehmeier M; Behrens G; Manns MP; Schmidt RE; Strassburg CP
Hepatology; 2006 Nov; 44(5):1324-32. PubMed ID: 17058217
[TBL] [Abstract][Full Text] [Related]
4. Urolithiasis in HIV-positive patients treated with atazanavir.
Couzigou C; Daudon M; Meynard JL; Borsa-Lebas F; Higueret D; Escaut L; Zucman D; Liotier JY; Quencez JL; Asselah K; May T; Neau D; Vittecoq D
Clin Infect Dis; 2007 Oct; 45(8):e105-8. PubMed ID: 17879904
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
6. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
7. Case presentation: nephrolithiasis in a patient treated with atazanavir.
Savini C; James C; Wilson S; Martin H; Szabo S; Scotto V
J Assoc Nurses AIDS Care; 2008; 19(3):225-7. PubMed ID: 18457764
[TBL] [Abstract][Full Text] [Related]
8. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.
Schmidt GA; Hoehns JD; Purcell JL; Friedman RL; Elhawi Y
J Am Board Fam Med; 2007; 20(4):411-6. PubMed ID: 17615423
[TBL] [Abstract][Full Text] [Related]
9. Does atazanavir cause lipodystrophy?
Gazzard BG; Moyle G
J HIV Ther; 2004 May; 9(2):41-4. PubMed ID: 15238875
[TBL] [Abstract][Full Text] [Related]
10. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.
Chan-Tack KM; Truffa MM; Struble KA; Birnkrant DB
AIDS; 2007 May; 21(9):1215-8. PubMed ID: 17502736
[TBL] [Abstract][Full Text] [Related]
11. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients.
Pollack TM; McCoy C; Stead W
Pharmacotherapy; 2009 Nov; 29(11):1386-91. PubMed ID: 19857154
[TBL] [Abstract][Full Text] [Related]
12. Atazanavir: new option for treatment of HIV infection.
Havlir DV; O'Marro SD
Clin Infect Dis; 2004 Jun; 38(11):1599-604. PubMed ID: 15156449
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
[TBL] [Abstract][Full Text] [Related]
14. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir.
Gianotti N; Guffanti M; Galli L; Margonato A; Chiaravalli G; Bigoloni A; Lazzarin A; Castagna A
AIDS; 2007 Jul; 21(12):1648-51. PubMed ID: 17630564
[TBL] [Abstract][Full Text] [Related]
15. Can boosted atazanavir induce hyperlipotrophy?
Dellamonica P
J Infect; 2006 Jun; 52(6):e189-90. PubMed ID: 16239035
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.
Colafigli M; Di Giambenedetto S; Bracciale L; Tamburrini E; Cauda R; De Luca A
HIV Med; 2008 Mar; 9(3):172-9. PubMed ID: 18217998
[TBL] [Abstract][Full Text] [Related]
17. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
Macassa E; Delaugerre C; Teglas JP; Jullien V; Tréluyer JM; Veber F; Rouzioux C; Blanche S
Pediatr Infect Dis J; 2006 Sep; 25(9):809-14. PubMed ID: 16940839
[TBL] [Abstract][Full Text] [Related]
18. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
Pineda JA; Santos J; Rivero A; Abdel-Kader L; Palacios R; Camacho A; Lozano F; Macías J;
J Antimicrob Chemother; 2008 Apr; 61(4):925-32. PubMed ID: 18276600
[TBL] [Abstract][Full Text] [Related]
19. [Evidence-based therapeutic drug monitoring of atazanavir].
Solas C; Muret P;
Therapie; 2011; 66(3):213-9. PubMed ID: 21819805
[TBL] [Abstract][Full Text] [Related]
20. [Adverse effects of atazanavir].
Palacios R; González M; Ruiz J; Santos J
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():41-4. PubMed ID: 20116616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]